Us2.aia Singapore-based medical technology developer, announced on Thursday that it has raised $15 million in a Series A round led by IHH Healthcare and Heal Partners, with participation from Pappas Capital and existing investors including Sequoia India, EDBI and Partech Ventures.
The new funds will be used to drive Us2.ai’s ambitious growth goals for clinical implementation in the United States, Europe and Asia, as well as the expansion of commercial activities with major pharmaceutical companies, laboratories of imaging research and providers worldwide, Us2.ai said. in a report.
“Us2.ai will increase patient access to echocardiography by providing a unique AI solution that completely automates study reading, with expert-like accuracy, but more than 30 times faster; leaving doctors in full control and with more time to spend with patients,” said Dr. Carolyn Lam, Senior Consultant Cardiologist at National Heart Center Singapore, Professor at Duke-National University of Singapore and co-founder of Us2.ai.
Meanwhile, Us2.ai CEO and co-founder James Hare said the company’s goal is to create a complete solution that goes beyond the existing industry standard of partial automation requiring manual intervention and providing limited measurements.
“Our software automatically processes complete echocardiographic studies of 2D and Doppler images from any vendor, in less than two minutes, delivering comprehensive echo reports, with fully explainable measurements, editable annotations, and conclusions for each chamber of the heart,” he added.
Us2.ai uses machine learning to automate the fight against heart disease. The company’s software tools improve clinical decision making and cardiovascular research for clinical trials using echocardiography, the safest and most common cardiac imaging modality. It connects imaging institutions and labs around the world on a platform of ready-to-use automation tools for view classification, segmentation, and federated learning across diverse anonymized patient cohorts and of diseases.
“Through investments in innovative digital health companies like Us2.ai, we seek to support and make state-of-the-art clinical tools and care (in this case, AI-powered echocardiogram analysis) more accessible and affordable for patients, and improve the delivery of physician care. This will speed up the diagnosis of heart disease for the public,” said IHH Executive Director and CEO Dr. Kelvin Loh.
Us2.ai has completed several projects with global pharmaceutical partners as well as a breakthrough endorsement study at Brigham & Women’s Hospital. Their patented software workflow was recently described in Lancet Digital Health, where external validation has been demonstrated in large, diverse studies of real-world patients.
“Heal is thrilled to support the company’s mission to automate the fight against cardiovascular disease, the number one killer worldwide. We are extremely impressed with the pace of development and the broad reach of Us2.ai’s cutting-edge technology. We look forward to helping it reach its potential on a global scale while democratizing access to this revolutionary tool for the early diagnosis of heart problems,” said HEAL Partner Martin Robinson.
HEAL is an early-stage acceleration and growth investment vehicle focused on income-generating growth companies in the healthcare, education and lifestyle sectors with potential to scale globally or industry disruption. It is led by a team of proven founders, investors and operators. It focuses on capitalizing on the opportunities created by new specialties and technologies in large and growing markets and has a strong commitment to the environment, social and governance (ESG).
Singapore MedTech Startup Stratificare Plans to Raise $12M in Pre-Series A